SCHEMBL16060013

SCHEMBL16060013

O=c1[nH]nc(C2CC2)[nH]1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16082062 0.91 ADORA2A (0.38) —
SCHEMBL22077239 0.71 LMNA (0.36) —
SCHEMBL16661295 0.67 CSNK1A1 (0.33) —
SCHEMBL2973055 0.63 — —
SCHEMBL18482643 0.63 ADORA2A (0.44) —
SCHEMBL18482642 0.63 ADORA2A (0.44) —
SCHEMBL21802311 0.60 PDE10A (0.38) —
SCHEMBL5795266 0.59 — —
SCHEMBL18912009 0.59 — —
SCHEMBL9532882 0.57 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4739393-A1 TETRAHYDROQUINAZOLINE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS Merck Sharp & Dohme LLC (US) 2026-05-13 — — EP disclosed
US-20250026759-A1 TETRAHYDROQUINAZOLINE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS MERCK SHARP & DOHME LLC (US) 2025-01-23 — — US disclosed
WO-2025014788-A1 TETRAHYDROQUINAZOLINE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS MERCK SHARP & DOHME LLC (US) 2025-01-16 — — WO disclosed
US-9193719-B2 1,2,4-triazol-5-ones and analogs exhibiting anti-cancer and anti-proliferative activities DECIPHERA PHARMACEUTICALS, LLC (US) 2015-11-24 — — US disclosed
US-20140296252-A1 1,2,4-TRIAZOL-5-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC (US) 2014-10-02 — — US disclosed
WO-2014145023-A1 1,2,4-TRIAZOL-5-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC (US) 2014-09-18 — — WO disclosed
Send feedback